Biofrontera Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Biofrontera Inc. (BFRI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $263.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $131.00K, a 33.16% decline year-over-year.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $132.00K, a 30.53% decline year-over-year.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $158.00K, a 15.51% decline year-over-year.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $186.00K, a 1.64% increase year-over-year.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $730.00K, a 0.27% increase from fiscal 2024.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $728.00K, a 30.00% increase from fiscal 2023.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $560.00K, a 14.24% decline from fiscal 2022.
- Biofrontera Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $653.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $263.00K 10-Q · filed 2026-08-13 | $421.00K derived: sum of 3 quarters · filed 2026-08-13 | $607.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $132.00K 10-Q · filed 2026-05-14 | $290.00K derived: sum of 2 quarters · filed 2026-05-14 | $476.00K derived: sum of 3 quarters · filed 2026-05-14 | $672.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $344.00K derived: sum of 2 quarters · filed 2026-03-19 | $540.00K derived: sum of 3 quarters · filed 2026-08-13 | $730.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $186.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $382.00K derived: sum of 2 quarters · filed 2026-08-13 | $572.00K 10-Q · filed 2025-11-12 | $759.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $196.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $386.00K 10-Q · filed 2026-08-13 | $573.00K derived: sum of 3 quarters · filed 2026-08-13 | $756.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $190.00K 10-Q · filed 2026-05-14 | $377.00K derived: sum of 2 quarters · filed 2026-05-14 | $560.00K derived: sum of 3 quarters · filed 2026-05-14 | $739.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $370.00K derived: sum of 2 quarters · filed 2026-03-19 | $549.00K derived: sum of 3 quarters · filed 2026-03-19 | $728.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $362.00K derived: sum of 2 quarters · filed 2025-11-12 | $541.00K 10-Q · filed 2025-11-12 | $711.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $358.00K 10-Q · filed 2025-08-13 | $528.00K derived: sum of 3 quarters · filed 2025-08-13 | $653.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $179.00K 10-Q · filed 2025-05-15 | $349.00K derived: sum of 2 quarters · filed 2025-05-15 | $474.00K derived: sum of 3 quarters · filed 2025-05-15 | $600.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $295.00K derived: sum of 2 quarters · filed 2025-03-20 | $421.00K derived: sum of 3 quarters · filed 2025-03-20 | $560.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $251.00K derived: sum of 2 quarters · filed 2024-11-14 | $390.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $265.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $139.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $653.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |